Recruiting

Calcific Total Occlusions

Sponsor:

SoundBite Medical Solutions, Inc.

Code:

NCT05551780

Conditions

Chronic Total Occlusion of Artery of the Extremities

Eligibility Criteria

Sex: All

Age: 19+

Healthy Volunteers: Not accepted

Interventions

SoundBite Crossing System

Study Details

Brief summary:

Prospective, multi-center, non-randomized, open label, clinical study intended to provide data to demonstrate safety and performance of the SoundBite Crossing System XS Peripheral.

Conditions

Chronic Total Occlusion of Artery of the Extremities

Study ID

NCT05551780

Start date

Feb 21, 2023

Status verified date

Jun, 2024

Completion date

Dec, 2024

Anticipated

Primary completion date

Nov, 2024

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 19+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Scheduled for interventional treatment of de-novo lesion(s) of the following native arteries:

1. CaTO-PAD: infrainguinal
2. CaTO-BTK: infrapopliteal
2. Have at least one chronic total occlusion (CTO) with no flow observed in the distal lesion except the flow from collateral circulation
3. Presenting with the following:

1. CaTO-PAD: claudication or CLI (Rutherford Clinical Category 2-5) of the target limb
2. CaTO-BTK Sub-Study: - Category 4 or 5 only for CaTO-BTK Sub-Study CaTO-PAD: claudication or CLI (Rutherford Clinical Category 2-5) of the target limb
4. Age of > 18 years
5. Have been informed of the nature of the study, agrees to participate, and has signed the approved study consent form
6. Target lesion calcification is at least moderate by PARC definition (see Section 15)
7. Target lesion is refractory as demonstrated by a failed attempt with a guidewire

Exclusion Criteria:

1. Any medical condition that would make subject an inappropriate candidate for interventional treatment as determined by the Investigator, including the following:

1. Glomerular filtration rate <30 ml/min
2. Mortality expected within 30 days
2. Already enrolled in an investigational interventional study that would interfere with study endpoints
3. Target lesion is crossed intraluminally with a conventional guidewire
4. Treatment of an inflow lesion prior to target lesion treatment results in no reflow, thrombus formation, abrupt closure, distal embolization, dissection or perforation requiring treatment
5. Women who are pregnant or breastfeeding

Study Design

Enrollment

130 participants

Anticipated

Allocation

Non randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: SoundBite Crossing System - PAD

Use of the SoundBite Crossing System to cross calcified chronic total occlusions (above-the-knee or below-the-knee)

experimental: SoundBite Crossing System - BTK

Use of the SoundBite Crossing System to cross calcified chronic total occlusions (below-the-knee)

Interventions

SoundBite Crossing System

Use of the SoundBite Crossing System to cross calcified chronic total occlusions

Primary outcome measure

  • Device Performance [ Time Frame: Day 0 ]
  • Device Safety [ Time Frame: Day 0 ]

Central Contacts and Locations

Locations

Palm Vascular Centers

Recruiting

Fort Lauderdale, Florida, United States, 33312

Contacts

Lifespan - The Miriam Hospital

Recruiting

Providence, Rhode Island, United States, 02906

Contacts

More Information

Sponsor

SoundBite Medical Solutions, Inc.

Last update posted

Jun 13, 2024

Last verified

Jun, 2024

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by SoundBite Medical Solutions, Inc. on 2024-06-13.